Crossmark

1343 A phase II trial of combination locoregional chemoimmunotherapy in recurrent platinum-sensitive ovarian cancer triggers a T lymphotactic response correlating with clinical outcomes

Crossref DOI link: https://doi.org/10.1136/jitc-2025-SITC2025.1343

Published Online: 2025-11-07

Published Print: 2025-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Radolec, Mackenzy

Orr, Brian

Strange, Mary

Zhang, Lixin

Cascio, Sandra

Falkenstein, Brian

Burak Tosun, A

Chakra Chennubhotla, S

Pullara, Filippo

Vlad, Anda

Edwards, Robert P
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03734692 at ClinicalTrials.gov

Documents that mention this clinical trial

799 Combination intraperitoneal chemoimmunotherapy triggers a T-cell chemotactic locoregional response in patients with recurrent platinum-sensitive ovarian cancer
https://doi.org/10.1136/jitc-2023-sitc2023.0799

1343 A phase II trial of combination locoregional chemoimmunotherapy in recurrent platinum-sensitive ovarian cancer triggers a T lymphotactic response correlating with clinical outcomes
https://doi.org/10.1136/jitc-2025-sitc2025.1343
License Information

License valid from 2025-10-31

Document is current

Any future updates will be listed below